Riverside, California 2021-09-21 05:42:31 –
Corpus Christi, Texas — First review of data on Pfizer’s COVID-19 vaccine for infants in the United States
The vaccine is given twice at 21-day intervals, as in adults.
However, the dose itself is one-third less than the adult dose. Doctors say it is routine to adjust the dose of vaccines and drugs for young children.
Pfizer said in the study that the vaccine was safe, well tolerated and evoked a strong antibody response.
He said the side effects were generally similar to those observed in participants aged 16 to 25 years. Approximately 2,300 infants were vaccinated in the trial and there was no shortage of volunteers.
“Of course, children are volunteered by their parents, who tend to be educated that they are often medical professionals,” said Dr. William Schaffner of the Vanderbilt University Medical Center. There are many other parents who want to give their children a chance to get vaccinated. ”
The data arrived a little earlier than expected and has not yet been peer reviewed.
It will then be shared with the FDA Panel for reviews that can take 4-6 weeks. The review may lead to an emergency use authorization review and the vaccine may be available around October 31, 2021.
There is an urgent need to vaccinate more children, with children accounting for nearly one-third of all COVID-19 cases currently reported in the United States.
“In our children’s hospital, hospitalization of perfectly normal and healthy children is done in a very serious way and in secret, and we obviously want to prevent it as much as possible,” Schaffner said. “.
Vaccine data from Moderna in this age group will be released shortly. This means that children of all school ages can be vaccinated with two vaccines.
Data on children under the age of 5 will be provided later this winter.
New data on Pfizer’s COVID-19 vaccine for kids Source link New data on Pfizer’s COVID-19 vaccine for kids